OBJECTIVE: Antibiotics are widely used by all specialties in the hospital setting. We evaluated previously defined high-risk antibiotic use in relation to Clostridioides difficile infections (CDIs). METHODS: We analyzed 2016-2017 data from 171 hospitals. High-risk antibiotics included second-, third-, and fourth-generation cephalosporins, fluoroquinolones, carbapenems, and lincosamides. A CDI case was a positive stool C. difficile toxin or molecular assay result from a patient without a positive result in the previous 8 weeks. Hospital-associated (HA) CDI cases included specimens collected >3 calendar days after admission or ≤3 calendar days from a patient with a prior same-hospital discharge within 28 days. We used the multivariable Poisson regression model to estimate the relative risk (RR) of high-risk antibiotic use on HA CDI, controlling for confounders. RESULTS: The median days of therapy for high-risk antibiotic use was 241.2 (interquartile range [IQR], 192.6-295.2) per 1,000 days present; the overall HA CDI rate was 33 (IQR, 24-43) per 10,000 admissions. The overall correlation of high-risk antibiotic use and HA CDI was 0.22 (P = .003), and higher correlation was observed in teaching hospitals (0.38; P = .002). For every 100-day (per 1,000 days present) increase in high-risk antibiotic therapy, there was a 12% increase in HA CDI (RR, 1.12; 95% CI, 1.04-1.21; P = .002) after adjusting for confounders. CONCLUSIONS: High-risk antibiotic use is an independent predictor of HA CDI. This assessment of poststewardship implementation in the United States highlights the importance of tracking trends of antimicrobial use over time as it relates to CDI.
OBJECTIVE: Antibiotics are widely used by all specialties in the hospital setting. We evaluated previously defined high-risk antibiotic use in relation to Clostridioides difficile infections (CDIs). METHODS: We analyzed 2016-2017 data from 171 hospitals. High-risk antibiotics included second-, third-, and fourth-generation cephalosporins, fluoroquinolones, carbapenems, and lincosamides. A CDI case was a positive stool C. difficile toxin or molecular assay result from a patient without a positive result in the previous 8 weeks. Hospital-associated (HA) CDI cases included specimens collected >3 calendar days after admission or ≤3 calendar days from a patient with a prior same-hospital discharge within 28 days. We used the multivariable Poisson regression model to estimate the relative risk (RR) of high-risk antibiotic use on HA CDI, controlling for confounders. RESULTS: The median days of therapy for high-risk antibiotic use was 241.2 (interquartile range [IQR], 192.6-295.2) per 1,000 days present; the overall HA CDI rate was 33 (IQR, 24-43) per 10,000 admissions. The overall correlation of high-risk antibiotic use and HA CDI was 0.22 (P = .003), and higher correlation was observed in teaching hospitals (0.38; P = .002). For every 100-day (per 1,000 days present) increase in high-risk antibiotic therapy, there was a 12% increase in HA CDI (RR, 1.12; 95% CI, 1.04-1.21; P = .002) after adjusting for confounders. CONCLUSIONS: High-risk antibiotic use is an independent predictor of HA CDI. This assessment of poststewardship implementation in the United States highlights the importance of tracking trends of antimicrobial use over time as it relates to CDI.
Authors: Katharina L van Santen; Jonathan R Edwards; Amy K Webb; Lori A Pollack; Erin O'Leary; Melinda M Neuhauser; Arjun Srinivasan; Daniel A Pollock Journal: Clin Infect Dis Date: 2018-07-02 Impact factor: 9.079
Authors: Kalvin Yu; Jay Rho; Marlene Morcos; Jim Nomura; Donald Kaplan; Keith Sakamoto; Doan Bui; Sandy Yoo; Jason Jones Journal: Am J Health Syst Pharm Date: 2014-06-15 Impact factor: 2.637
Authors: F Cao; C X Chen; M Wang; H R Liao; M X Wang; S Z Hua; B Huang; Y Xiong; J Y Zhang; Y L Xu Journal: J Hosp Infect Date: 2017-08-24 Impact factor: 3.926
Authors: Marya D Zilberberg; Ying P Tabak; Dawn M Sievert; Karen G Derby; Richard S Johannes; Xiaowu Sun; L Clifford McDonald Journal: Infect Control Hosp Epidemiol Date: 2011-07 Impact factor: 3.254
Authors: Sophia V Kazakova; James Baggs; L Clifford McDonald; Sarah H Yi; Kelly M Hatfield; Alice Guh; Sujan C Reddy; John A Jernigan Journal: Clin Infect Dis Date: 2020-01-01 Impact factor: 9.079
Authors: Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245
Authors: José Francisco García-Rodríguez; Belén Bardán-García; Pedro Miguel Juiz-González; Laura Vilariño-Maneiro; Hortensia Álvarez-Díaz; Ana Mariño-Callejo Journal: Antibiotics (Basel) Date: 2020-12-26
Authors: K Ashley Jones; Udodirim N Onwubiko; Mary Elizabeth Sexton; Zanthia Wiley; Julianne Kubes; Benjamin Albrecht; Kristen Paciullo; Jessica Howard-Anderson; Sujit Suchindran; Ronald Trible; Jesse T Jacob; Sarah H Yi; Dana Goodenough; Scott K Fridkin Journal: Antimicrob Steward Healthc Epidemiol Date: 2021-10-22
Authors: Katherine E Goodman; Sara E Cosgrove; Lisa Pineles; Laurence S Magder; Deverick J Anderson; Elizabeth Dodds Ashley; Ronald E Polk; Hude Quan; William E Trick; Keith F Woeltje; Surbhi Leekha; Anthony D Harris Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 20.999
Authors: Laura Puzniak; Karri A Bauer; Kalvin C Yu; Pamela Moise; Lyn Finelli; Gang Ye; Carisa De Anda; Latha Vankeepuram; Vikas Gupta Journal: Open Forum Infect Dis Date: 2021-05-26 Impact factor: 3.835